Trial 2N-23-5


A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Nonsmall Cell Lung Cancer (HARMONi-3)

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Chemotherapy: Systemic
Randomized: Yes
USC Satellite Location: USC Koreatown, USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Robert Hsu, M.D.
Other Trial Staff:  Mary Ordaz, D.M., Niranjan Bhatt, D.M., Sreebharathy Venkatesh, D.M., Sana Mutalib, Coordinator, Andrew Zeng, Coordinator, Thomas Won, Coordinator, Sophia Marmolejo, Coordinator, Sandy Tran, Coordinator, Azucena Vera, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.